Hyperactivated Ras regulates many oncogenic pathways in several malignant
human cancers including glioblastoma and it is an attractive target for cancer
therapies. Ras activation in cancer cells drives protein internalization via
macropinocytosis as a key nutrient-gaining process. By utilizing this unique
endocytosis pathway, here we create a biologically inspired nanostructure that can
induce cancer cells to ‘drink drugs' for targeting activating
transcription factor-5 (ATF5), an overexpressed anti-apoptotic transcription factor
in glioblastoma. Apolipoprotein E3-reconstituted high-density lipoprotein is used to
encapsulate the siRNA-loaded calcium phosphate core and facilitate it to penetrate
the blood–brain barrier, thus targeting the glioblastoma cells in a
macropinocytosis-dependent manner. The nanostructure carrying ATF5 siRNA exerts
remarkable RNA-interfering efficiency, increases glioblastoma cell apoptosis and
inhibits tumour cell growth both in vitro and in xenograft tumour models.
This strategy of targeting the macropinocytosis caused by Ras activation
provides a nanoparticle-based approach for precision therapy in glioblastoma and
other Ras-activated cancers.